|
Dianthus Therapeutics Inc (DNTH) |
|
Dianthus Therapeutics Inc
DNTH's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Dianthus Therapeutics Inc growth rates, revenue grew
in III. Quarter 2023 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
deterioration of revenues by -4.75 %
Dianthus Therapeutics Inc net loss decreased from $-16 millions, to $-15 millions in III. Quarter 2023,
• More on DNTH's Growth
|
|
Dianthus Therapeutics Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 0.78 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 118.35.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.7.
• More on DNTH's Valuation
|
|
|
|
|
Dianthus Therapeutics Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 0.78 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 118.35.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.7.
Dianthus Therapeutics Inc Price to Book Ratio is at 0.61 lower than Industry Avg. of 84.11. and higher than S&P 500 Avg. of 0
• More on DNTH's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com